Evidence map›Paper›PMID 21710576›Full record

ArticleJournal of tissue engineering and regenerative medicine2012

Phenotypic and functional characterization of human bone marrow stromal cells in hollow-fibre bioreactors.

Matthew Li, Arno W Tilles, Jack M Milwid, Mohamed Hammad, Jungwoo Lee, Martin L Yarmush, Biju Parekkadan

Abstract read
In one paragraph

Article in Journal of tissue engineering and regenerative medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Convergence of Cell Pharmacology and Drug Delivery.Stem cells translational medicine · 2019
    Article
  4. Review
  5. Article
  6. Article
  7. Artificial Bone via Bone Tissue Engineering: Current Scenario and Challenges.Tissue engineering and regenerative medicine · 2017
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Matthew LiCenter for Engineering in Medicine and Surgical Services, Massachusetts General Hospital, Harvard Medical School, Shriners Hospital for Children, Boston, MA, USA.
Arno W Tilles
Jack M Milwid
Mohamed Hammad
Jungwoo Lee
Martin L Yarmush
Biju Parekkadan

Funding

Bio-MicroElectroMechanical Systems Resource CenterP41EB002503 · NIBIB · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET · 2004 to 2018
$17.4M
HEPATIC TISSUE ENGINEERINGR01DK043371 · NIDDK · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI YARMUSH, MARTIN L · 1992 to 2006
$2.4M
Peripheral Tissue Antigen Display by Mesenchymal Stem CellsK01DK087770 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI PAREKKADAN, BIJU · 2010 to 2014
$682k
A Mesenchymal Stem Cell Bioreactor for the Active Treatment of Acute Renal FailurR43DK085766 · NIDDK · SENTIEN BIOTECHNOLOGIES, INC. · PI MILLER, BRIAN, TILLES, ARNO W · 2010 to 2011
$565k
Cellular Composite Device for Combination Therapy of Acute Liver FailureR21DK085267 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI YARMUSH, MARTIN L · 2010 to 2011
$483k
Elucidating Essential Components of Bone Marrow MetastasisK99CA163671 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI LEE, JUNGWOO · 2012 to 2013
$179k
NCI NIH HHS K99 CA163671NIBIB NIH HHS P41 EB002503NIDDK NIH HHS K01 DK087770NIDDK NIH HHS K01DK087770NIDDK NIH HHS R01 DK043371NIDDK NIH HHS R01DK43371NIDDK NIH HHS R21 DK085267NIDDK NIH HHS R21DK085267NIDDK NIH HHS R43 DK085766
6 · The paper itself

Abstract

The transplantation of human bone marrow stromal cells (BMSCs) is a novel immunotherapeutic approach that is currently being explored in many clinical settings. Evidence suggests that the efficacy of cell transplantation is directly associated with soluble factors released by human BMSCs. In order to harness these secreted factors, we integrated BMSCs into large-scale hollow-fibre bioreactor devices in which the cells, separated by a semipermeable polyethersulphone (PES) membrane, can directly and continuously release therapeutic factors into the blood stream. BMSCs were found to be rapidly adherent and exhibited long-term viability on PES fibres. The cells also preserved their immunophenotype under physiological fluid flow rates in the bioreactor, and exhibited no signs of differentiation during device operation, but still retained the capacity to differentiate into osteoblastic lineages. BMSC devices released growth factors and cytokines at comparable levels on a per-cell basis to conventional cell culture platforms. Finally, we utilized a potency assay to demonstrate the therapeutic potential of the collected secreted factors from the BMSC devices. In summary, we have shown that culturing BMSCs in a large-scale hollow-fibre bioreactor is feasible without deleterious effects on phenotype, thus providing a platform for collecting and delivering the paracrine secretions of these cells.

Indexed as

BioreactorsParacrine CommunicationBone Marrow CellsCell Culture TechniquesCells, CulturedHumansIntercellular Signaling Peptides and ProteinsStromal CellsIntercellular Signaling Peptides and Proteins

Identifiers

PMID21710576
PMCPMC3183117

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.